7.85

0.77% 0.06

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $7.85, with a volume of 352.44K. It is up +0.77% in the last 24 hours and down -6.44% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$7.79

Open:

$7.79

24h Volume:

352.44K

Relative Volume:

0.35

Market Cap:

$2.43B

Revenue:

$2.68B

Net Income/Loss:

$-184.45M

P/E Ratio:

-392.50

EPS:

-0.02

Net Cash Flow:

$229.23M

1W Performance:

-2.73%

1M Performance:

-6.44%

6M Performance:

+19.85%

1Y Performance:

+36.28%

1-Day Range:

$7.71

$7.85

1-Week Range:

$7.57

$8.05

52-Week Range:

$5.01

$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1169)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2024-12-08

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	7.85	2.43B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	164.70	74.31B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.74	44.04B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.17	41.75B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	22.42	25.40B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	12.40	14.80B	15.05B	-883.30M	1.89B	-0.74

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

Dec 23, 2024

Investors Buy High Volume of Amneal Pharmaceuticals Call Options (NASDAQ:AMRX) - MarketBeat

Dec 23, 2024

Epinephrine Autoinjector Market Growth, Trends & Forecast - openPR

Dec 23, 2024

Dec 22, 2024

State Street Corp Boosts Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Dec 22, 2024

Dec 21, 2024

82,596 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by Wellington Management Group LLP - MarketBeat

Dec 21, 2024

Dec 20, 2024

Teva loses US appeal to keep inhaler patents on FDA protected drug list - Reuters

Dec 20, 2024

Dec 19, 2024

Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.com - MarketBeat

Dec 19, 2024

Dec 17, 2024

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5%Here's What Happened - MarketBeat

Dec 17, 2024

Dec 15, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average Price Target from Analysts - MarketBeat

Dec 15, 2024

BNP Paribas Financial Markets Sells 402,852 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Dec 15, 2024

Dec 13, 2024

Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Australia

Dec 13, 2024

Dec 12, 2024

Parkinson's Disease Market to Reach New Heights in Growth - openPR

Dec 12, 2024

Dec 11, 2024

SERD Therapeutics Market Key Players AnalysisAmneal - openPR

Dec 11, 2024

Dec 10, 2024

Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve

Dec 10, 2024

Jacobs Levy Equity Management Inc. Sells 189,881 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Dec 10, 2024

Dec 09, 2024

Charles Schwab Investment Management Inc. Buys 202,863 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Dec 09, 2024

Dec 06, 2024

Walleye Capital LLC Invests $1.10 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Dec 06, 2024

Dec 05, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat

Dec 05, 2024

Dec 04, 2024

Amneal to Participate at Upcoming Investor Conferences - BioSpace

Dec 04, 2024

Amneal Pharmaceuticals Leadership to Present at Major Healthcare Investment Conferences - StockTitan

Dec 04, 2024

Dec 02, 2024

Quantbot Technologies LP Grows Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Dec 02, 2024

Nov 26, 2024

Amneal Pharmaceuticals director John Kiely sells $142,946 in stock By Investing.com - Investing.com Australia

Nov 26, 2024

Amneal Pharmaceuticals director John Kiely sells $142,946 in stock - Investing.com India

Nov 26, 2024

Insider Sell: Deborah Autor Sells 40,000 Shares of Amneal Pharma - GuruFocus.com

Nov 26, 2024

Nov 25, 2024

Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 - GlobeNewswire Inc.

Nov 25, 2024

Amneal Set To Debut US Byetta Competition – Two Decades After Market Entry - Citeline

Nov 25, 2024

Nov 23, 2024

Premature Ejaculation Treatment Market to Grow by USD 1.46 Billion (2024-2028), Boosted by Effective Off-Label Drugs, Market Evolution Powered by AITechnavio - The Malaysian Reserve

Nov 23, 2024

Nov 22, 2024

Amneal Pharmaceuticals exec sells shares worth $114,786 - Investing.com India

Nov 22, 2024

Amneal Pharmaceuticals exec sells shares worth $114,786 By Investing.com - Investing.com Nigeria

Nov 22, 2024

Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN

Nov 22, 2024

Amneal files again for FDA approval of first dihydroergotamine autoinjector - Pharmaceutical Technology

Nov 22, 2024

Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide By Investing.com - Investing.com Canada

Nov 22, 2024

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - BioSpace

Nov 22, 2024

Nov 21, 2024

Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved - MarketWatch

Nov 21, 2024

Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide - Investing.com India

Nov 21, 2024

GSA Capital Partners LLP Has $452,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Nov 21, 2024

Senior VP Of Amneal Pharmaceuticals Sold 76% Of Their Shares - Simply Wall St

Nov 21, 2024

Nov 20, 2024

Amneal Pharmaceuticals Q3 2024 Earnings Preview - MSN

Nov 20, 2024